News | February 02, 2015

Biosensors Enters Into Distribution Agreement with Veryan for BioMimics 3D Stent

Stent mimics natural geometry of the human vascular system

Stents, BioMimics 3D, Veryan Medical, Biosensors International Group

Image courtesy of Veryan Medical

February 2, 2015 — Biosensors International Group has announced a distribution agreement with Veryan Medical Ltd. for BioMimics 3D, a nitinol stent with three-dimensional helical geometry designed for use in the superficial femoral artery.  The agreement covers certain international markets, but excludes the United States and Japan.

The BioMimics 3D stent incorporates Veryan’s patented 3-D helical technology, an advanced stent design that promotes natural swirling blood flow to elevate wall shear stress, which has been shown to reduce neointimal hyperplasia. The 3-D advanced design has also been shown to improve the biomechanical performance of the stent when implanted in the femoropopliteal artery, mitigating the risk of stent fracture and vessel kinking.  An estimated 200,000 endovascular femoropopliteal procedures are performed each year in the EU alone.

Two-year data from the Mimics study have confirmed that BioMimics 3D provides significant improvement in long-term patency compared to a straight nitinol control stent in patients undergoing femoropopliteal artery intervention. The data indicates a correlation between primary patency and stent curvature. In addition, a 12-month Landmark analysis reinforces the longer term benefit of Veryan’s helical stent technology and shows a statistically significant improvement in the Kaplan-Meier estimate of survival from clinically-driven TLR through 24 months, compared to the control stent.

Veryan received CE Mark approval for the BioMimics 3D stent in September 2012. Biosensors expects to commence active promotion of BioMimics 3D in Q1 2015.

For more information:,



Related Content

Videos | Stents | September 11, 2018
This is an animation showing how the dedicated bifurcation stent developed by Advanced Bifurcation Systems (ABS) is d
Elixir Medical Corporation Unveils Transformational DynamX Stent Featuring Adaptive Segments that Uncage the Stented Artery
News | Stents | January 25, 2018
January 25, 2018 – Elixir Medical Corporation, a leader in the development of breakthrough adaptive remodeling techno
The TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

The presentation of the ESC late-breaker TIDES-ACS results show us that the Optimax stent is noninferior in patients with acute coronary syndrome compared to Synergy.

News | Stents | November 24, 2017
November 24, 2017 – During a late-breaking session at the European Society of Cardiology (ESC) 2017 meeting, presente
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

OCT comparison between the Combo vs. Xience stents in the HARMONEE study.

Feature | Stents | November 08, 2017
November 8, 2017 – New results from the HARMONEE Japan/U.S.
FDA Approves COBRA REDUCE Trial of 14-Day DAPT With CeloNova Stent
News | Stents | October 27, 2017
CeloNova BioSciences Inc. announced the U.S. Food and Drug Administration (FDA) approved expansion of CeloNova's...
CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017
March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc.
OCT, intravascular imaging, stent, good stent apposition on vessel wall, TRANSFORM-OCT study

An OCT image showing good stent strut apposition against the vessel wall.

News | Stents | January 13, 2017
January 13, 2017 — Results from TRANSFORM-OCT, a prospective, randomized trial using optical coherence tomography (OC
EXCEL Trial, TCT 2016, drug-eluting stents, CABG, surgery left main heart disease, LMCAD

Gregg W. Stone, M.D., presenting the EXCEL data at TCT 2016 during a standing room only late-breaking trial session.

Feature | Stents | January 12, 2017 | Dave Fornell
The biggest news from the 2016 Transcatheter Cardiovascular Therapeutics (TCT) meeting this past fall was the results
Biotronik's Osiro stent, prison IV trial

Biotronik's Osiro ultra-thin strut, sirolimus-eluting stent.

News | Stents | November 09, 2016
November 9, 2016 – Results from a randomized, multicenter trial failed to show non-inferiority of hybrid, ultra-thin
Overlay Init